Methotrexat Ebewe (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is needed to produce tetrahydrofolate, a form of folate essential for making DNA, RNA, and proteins. By limiting these building blocks, the drug slows the proliferation of rapidly dividing cells such as cancer cells and activated immune cells, and it also promotes anti‑inflammatory pathways.

The exact dose of Methotrexat Ebewe is individualized by the prescribing clinician based on the specific indication, disease severity, patient weight, renal and hepatic function, and response to therapy. No standard dosing regimen is provided here; the prescriber will calculate the appropriate amount for each patient.

Methotrexat Ebewe is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal malformations and loss. It is also not recommended for breastfeeding mothers, as the drug can be excreted in breast milk and may harm the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and any required import documentation.

Methotrexat Ebewe belongs to the folate antagonist class, similar to drugs such as pemetrexed and leflunomide. Compared with newer agents, methotrexate has a long‑standing safety record, is available in multiple routes of administration, and is often less expensive, though it may require more intensive monitoring for hepatic and hematologic toxicity.

Methotrexat Ebewe should be stored at controlled room temperature, below 25 °C, in its original packaging. The container should be kept away from moisture, direct sunlight, and extreme temperatures to maintain product stability.

The product is supplied as a sterile injectable solution and is administered by qualified healthcare professionals via intra‑arterial, intramuscular, or intrathecal injection, depending on the therapeutic indication and clinical protocol.

The most critical risks include severe bone‑marrow suppression leading to pancytopenia, hepatotoxicity that can progress to fibrosis or cirrhosis, pulmonary toxicity such as interstitial pneumonitis, acute renal failure, and life‑threatening infections due to immunosuppression. Prompt medical evaluation is required if any of these occur.

Methotrexat Ebewe is contraindicated in pregnant women, individuals with severe liver disease, uncontrolled infections, or significant renal impairment. Patients with known hypersensitivity to methotrexate or any component of the formulation should also avoid its use.